Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Fumarate, Tenofovir Disoproxil

ApprovedSmall molecule

AANRS, Emerging Infectious Diseases

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis B VirusRecruiting

Hepatitis B VirusApproved

Recruiting

Timeline

Expected Milestones

Q1 2028

ApprovedRecruiting

Hepatitis B Virus

NCT05403047

Clinical

Trials by Indication[1]

Hepatitis B Virus1 trial

Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women Infected With Hepatitis B Virus (HBeAg Positive or With a High Viral Load) and Whose Newborns Had Been Vaccinated at Birth

Recruiting·AANRS, Emerging Infectious Diseases·Approved·NCT05403047·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fumarate, Tenofovir Disoproxil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fumarate, Tenofovir Disoproxil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fumarate, Tenofovir Disoproxil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ANRS, Emerging Infectious Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AANRS, Emerging Infectious Diseases

Related News